^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colon Cancer

    Related cancers:
    Apply
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (NCT02997228)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/19/2018
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • MSI • MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/05/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CD4
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/16/2017
    Primary completion :
    04/02/2025
    Completion :
    04/02/2025
    MLH1 • MSH6 • MSH2 • CD4
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca (NCT03919292)
    Phase 1/2
    Virginia Commonwealth University
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    05/01/2019
    Primary completion :
    05/31/2025
    Completion :
    05/31/2026
    EGFR
    |
    EGFR mutation • RAS mutation
    |
    Nerlynx (neratinib)
    A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) (NCT05253651)
    Phase 3
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/24/2022
    Primary completion :
    04/03/2026
    Completion :
    07/27/2029
    HER-2
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • levoleucovorin calcium
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (NCT05419011)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    05/08/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    COLON ERDERLY LOW DOSE (CELOW) (NCT06840977)
    Phase N/A
    Matteo Clavarezza
    Not yet recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/01/2025
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    BRAF
    Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) (NCT02980510)
    Phase 2
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/01/2016
    Primary completion :
    12/01/2025
    Completion :
    01/01/2026
    KRAS • RAS
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) (MK-3475-016) (NCT04098068)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    01/25/2018
    Primary completion :
    05/15/2022
    Completion :
    02/05/2025
    TMB
    |
    Keytruda (pembrolizumab)
    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    08/09/2021
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    HER-2 • TP53 • ATM • RAS • CD4
    |
    HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
    Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer (BGB-A317-214) (NCT05116085)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/26/2022
    Primary completion :
    09/26/2023
    Completion :
    01/01/2027
    MSI
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr)
    Endoscopic Surveillance in Serrated Polyposis Syndrome and Low-risk of Advanced Neoplasia (NCT04906343)
    Phase N/A
    Hospital Universitario de Móstoles
    Completed
    Last update posted :
    02/18/2025
    Initiation :
    06/05/2021
    Primary completion :
    10/02/2024
    Completion :
    11/22/2024
    KRAS • BRAF
    Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer (NCT00819208)
    Phase N/A
    Canadian Cancer Trials Group
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/02/2009
    Primary completion :
    12/15/2029
    Completion :
    12/15/2030
    CEACAM5
    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (ST316-101) (NCT05848739)
    Phase 1
    Sapience Therapeutics
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    PD-L1 • MSI • BRCA
    |
    PD-L1 expression • MSI-H/dMMR • BRCA mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316
    Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (NCT00217737)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    09/06/2005
    Primary completion :
    08/31/2025
    Completion :
    08/31/2025
    MSI • MSH2
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) (NCT05482516)
    Phase 3
    Georgetown University
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/29/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2028
    CD4
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (ECLYPse) (NCT06640166)
    Phase 2
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    06/03/2024
    Primary completion :
    12/31/2025
    Completion :
    06/30/2026
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium
    FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (NCI-2022-09458) (NCT05627635)
    Phase 1/2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    05/03/2023
    Primary completion :
    10/07/2025
    Completion :
    10/07/2025
    POLE
    |
    POLE mutation
    |
    Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer (NCT02138617)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    05/01/2014
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    UGT1A1
    |
    UGT1A1*1*1
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (NCT01814501)
    Phase 2
    John Hays
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    02/01/2013
    Primary completion :
    08/06/2018
    Completion :
    08/06/2018
    KRAS
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NCT05174169)
    Phase 2/3
    NRG Oncology
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/10/2022
    Primary completion :
    03/10/2029
    Completion :
    03/10/2030
    MSI
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer (NCT05999812)
    Phase 2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/19/2023
    Primary completion :
    10/01/2026
    Completion :
    10/01/2028
    BRAF • MSI • MLH1 • MSH6 • MSH2 • CD4
    |
    BRAF V600E • BRAF V600 • RAS wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer (NCT03712943)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    01/29/2025
    Initiation :
    10/23/2018
    Primary completion :
    09/01/2021
    Completion :
    01/18/2024
    KRAS
    |
    RAS wild-type
    |
    Opdivo (nivolumab) • Stivarga (regorafenib)
    Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (NCT04362839)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    05/27/2020
    Primary completion :
    09/13/2025
    Completion :
    09/13/2025
    BRAF
    |
    BRAF wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Stivarga (regorafenib)
    SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial (NCT04599140)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/17/2025
    Initiation :
    10/14/2020
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    BRAF • CD8 • CD4 • CD69 • IRF2
    |
    Opdivo (nivolumab) • SX-682
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (SWOG S1613) (NCT03365882)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    01/14/2025
    Initiation :
    11/27/2017
    Primary completion :
    11/01/2022
    Completion :
    11/30/2025
    HER-2 • KRAS • BRAF • NRAS
    |
    BRAF V600E • HER-2 amplification • BRAF V600
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan • Trazimera (trastuzumab-qyyp)
    Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer (CA209-8LC) (NCT03711058)
    Phase 1/2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    01/13/2025
    Initiation :
    01/17/2019
    Primary completion :
    06/14/2022
    Completion :
    06/30/2025
    KRAS • BRAF
    |
    KRAS wild-type • BRAF wild-type • NRAS wild-type
    |
    Opdivo (nivolumab) • Aliqopa (copanlisib)
    Combination Therapy in Cancers With Mutations in DNA Repair Genes (NCT05694715)
    Phase 1
    University of California, San Francisco
    Recruiting
    Last update posted :
    12/18/2024
    Initiation :
    05/23/2023
    Primary completion :
    01/31/2028
    Completion :
    01/31/2028
    BRCA1 • BRCA2
    |
    Zejula (niraparib) • irinotecan
    CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (CENDIFOX) (NCT05121038)
    Phase 1/2
    Anup Kasi
    Active, not recruiting
    Last update posted :
    12/17/2024
    Initiation :
    10/20/2021
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    BRAF
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract (SOCRATE) (NCT06728358)
    Phase N/A
    Fondazione Policlinico Universitario Agostino G...
    Active, not recruiting
    Last update posted :
    12/11/2024
    Initiation :
    12/01/2024
    Primary completion :
    11/30/2028
    Completion :
    12/01/2028
    GATA6
    Phase I Trial of Adagrasib (MRTX849) in Combination with Cetuximab and Irinotecan in Patients with Colorectal Cancer (NCT05722327)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    12/09/2024
    Initiation :
    12/06/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2027
    KRAS • UGT1A1
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • irinotecan • Krazati (adagrasib)
    Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (NCT03761914)
    Phase 1/2
    Sellas Life Sciences Group
    Completed
    Last update posted :
    11/19/2024
    Initiation :
    09/30/2019
    Primary completion :
    07/05/2022
    Completion :
    10/27/2022
    HER-2 • KRAS • PGR • WT1 • BRCA • MUC16
    |
    HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation
    |
    Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (NCT04776148)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    10/29/2024
    Initiation :
    03/29/2021
    Primary completion :
    02/20/2023
    Completion :
    09/27/2024
    EGFR • KRAS • BRAF • MSI
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    Window of Opportunity Study in Colorectal Cancer (NCT03984578)
    Phase 2
    National Cancer Centre, Singapore
    Recruiting
    Last update posted :
    10/14/2024
    Initiation :
    06/12/2019
    Primary completion :
    02/28/2025
    Completion :
    02/28/2025
    IFNG
    |
    IFNG expression
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin
    Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study (NCT06575127)
    Phase 2
    Al-Azhar University
    Recruiting
    Last update posted :
    08/28/2024
    Initiation :
    08/17/2024
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    KRAS • BRAF
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (KEYNOTE-A10) (NCT03058289)
    Phase 1/2
    Intensity Therapeutics, Inc.
    Completed
    Last update posted :
    08/13/2024
    Initiation :
    02/09/2017
    Primary completion :
    02/22/2023
    Completion :
    02/22/2023
    MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)
    NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) (NCT05197322)
    Phase 2
    University College, London
    Recruiting
    Last update posted :
    08/05/2024
    Initiation :
    07/20/2022
    Primary completion :
    02/01/2026
    Completion :
    12/01/2028
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors (NCT06508307)
    Phase 1
    GONGCHU Biotechnology Co., Ltd
    Recruiting
    Last update posted :
    07/18/2024
    Initiation :
    04/26/2023
    Primary completion :
    01/01/2025
    Completion :
    06/01/2025
    IFNG • IL6 • TNFA • CD4